Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation.
Abouna
G M
GM
Division of Transplantation Surgery, Hahnemann University, Philadelphia, Pennsylvania 19102-1192.
Kumar
M S
MS
Stephan
R
R
Prior
J E
JE
Lyons
P
P
Bulova
S I
SI
al-Abdullah
I H
IH
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007223:Infant; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine